Catherine Sanders
Overview
Explore the profile of Catherine Sanders including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1605
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Siegel S, DeWolf S, Schmalz J, Saber W, Dong J, Martens M, et al.
medRxiv
. 2025 Mar;
PMID: 40061351
Successful hematopoietic cell transplant requires immunosuppression to prevent graft-versus-host disease (GVHD), a lethal, T-cell-mediated post-transplant complication. The phase 3 BMT CTN 1703 trial demonstrated superior GVHD-free/relapse-free survival for post-transplant cyclophosphamide...
2.
Borron A, Berg A, Jones C, Lamm A, Sanders C, Southall H, et al.
Health Promot Pract
. 2023 Mar;
24(1_suppl):56S-67S.
PMID: 36999491
This study explored the relationship between existing community resources and community leaders' perceptions of resilience and rural health during COVID-19. Observational data of material capitals (e.g., grocery stores and physical...
3.
Greenberger L, Saltzman L, Gruenbaum L, Xu J, Reddy S, Senefeld J, et al.
Blood Cancer Discov
. 2022 Sep;
3(6):481-489.
PMID: 36074641
Significance: This study represents the first investigation of SARS-CoV-2-specific immune responses to vaccination in a patient registry using an NGS-based method for T-cell receptor repertoire-based analysis combined with anti-spike antibody...
4.
Rawat A, Mithani N, Sanders C, Namugosa R, Payne B, Mitchell-Foster S, et al.
J Cancer Educ
. 2022 Apr;
38(2):618-624.
PMID: 35384556
Uganda has high incidence rates of cervical cancer (47.5/100,000/year) due to limited screening access. In settings where men hold most of the decision-making power, they play an important role in...
5.
Biavati L, Huff C, Ferguson A, Sidorski A, Stevens M, Rudraraju L, et al.
Clin Cancer Res
. 2021 Oct;
27(24):6696-6708.
PMID: 34667029
Purpose: This proof-of-principle clinical trial evaluated whether an allogeneic multiple myeloma GM-CSF-secreting vaccine (MM-GVAX) in combination with lenalidomide could deepen the clinical response in patients with multiple myeloma in sustained...
6.
Rawat A, Sanders C, Mithani N, Amuge C, Pedersen H, Namugosa R, et al.
Int J Gynaecol Obstet
. 2020 Oct;
152(1):103-111.
PMID: 33128778
Objective: To understand the knowledge, preferences, and barriers for self-collected cervical cancer screening (SC-CCS) and follow-up care at the individual and health system level to inform the implementation of community-based...
7.
Leick M, Gittelman R, Yusko E, Sanders C, Robins H, DeFilipp Z, et al.
Biol Blood Marrow Transplant
. 2020 May;
26(9):1567-1574.
PMID: 32417490
Delayed reconstitution of the immune system is a long-recognized complication after allogeneic hematopoietic cell transplantation (HCT). Specifically, loss of T cell diversity has been thought to contribute to infectious complications,...
8.
Ramien C, Yusko E, Engler J, Gamradt S, Patas K, Schweingruber N, et al.
Cell Rep
. 2019 Oct;
29(4):810-815.e4.
PMID: 31644905
Identifying T cell clones associated with human autoimmunity has remained challenging. Intriguingly, many autoimmune diseases, including multiple sclerosis (MS), show strongly diminished activity during pregnancy, providing a unique research paradigm...
9.
Palakurthi S, Kuraguchi M, Zacharek S, Zudaire E, Huang W, Bonal D, et al.
Cancer Immunol Res
. 2019 Jul;
7(9):1457-1471.
PMID: 31331945
The success of targeted or immune therapies is often hampered by the emergence of resistance and/or clinical benefit in only a subset of patients. We hypothesized that combining targeted therapy...
10.
Agdashian D, ElGindi M, Xie C, Sandhu M, Pratt D, Kleiner D, et al.
Cancer Immunol Immunother
. 2019 Jan;
68(4):599-608.
PMID: 30688989
Background: Checkpoint inhibitors have recently been approved for the treatment of patients with hepatocellular carcinoma (HCC). However, biomarkers, which will help identify patients responding to therapy, are missing. We recently...